-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Invivo Therapeutics Holdings Corp. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2021 to Q3 2023.
- Invivo Therapeutics Holdings Corp. Income Tax Expense (Benefit) for the quarter ending September 30, 2023 was $0.000.
- Invivo Therapeutics Holdings Corp. Income Tax Expense (Benefit) for the twelve months ending September 30, 2023 was $0.000.
- Invivo Therapeutics Holdings Corp. annual Income Tax Expense (Benefit) for 2022 was $0.000.
- Invivo Therapeutics Holdings Corp. annual Income Tax Expense (Benefit) for 2021 was $0.000.
- Invivo Therapeutics Holdings Corp. annual Income Tax Expense (Benefit) for 2020 was $0.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)